In patients with hyperlipidemia and cardiovascular disease, does the addition of a PCSK9 inhibitor decrease the incidence of subsequent cardiovascular events? : Evidence-Based Practice

Secondary Logo

Journal Logo

Advanced Search

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid
HELPDESK ANSWERS

In patients with hyperlipidemia and cardiovascular disease, does the addition of a PCSK9 inhibitor decrease the incidence of subsequent cardiovascular events?

Monroe, Lizzie MD; Evans, Tanner MD; Thacker, Thomas DO, MS; Streicher Green, Vanessa DO

Author Information

UT Nashville Family Medicine Residency, Murfreesboro, TN

The authors declare no conflicts of interest.

doi: 10.1097/EBP.0000000000001239
  • Buy
Copyright © 2021 by Family Physicians Inquiries Network, Inc.